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ABSTRACT 
Objective: To evaluate the synergistic protective effect of Momordica charantia and Phyllanthus amarus combination (MC+PA) of doses 200 and 
400 mg/kg on the liver in different experimental models of hepatotoxicity. 
Methods: The hepatoprotective activity was evaluated in ethanol and anti-tubercular drugs (isoniazid-INH, rifampicin-RIF) induced hepatotoxicity 
models. Hepatotoxicity in both models was induced to all groups except the normal control. Intoxicated rats were treated with silymarin and 
various doses of MC+PA for 8 d in ethanol-induced and 21 d in INH+RIF induced hepatotoxicity models. At the completion of study, the biochemical 
markers and the anti-oxidant status (SOD and MDA) were measured and also the histopathological evaluation of the liver tissue was carried out. 
Results: Combination therapy remarkably reduced the elevated profile of the biochemical markers and thereby improved the anti-oxidant status, 
thus exhibiting the synergistic hepatoprotective effect when compared with the positive control group (p<0.001). Histopathological evaluation 
demonstrated that MC+PA decreased the liver damage significantly in comparison with the positive group. 
Conclusion: The current work suggests that the combined extract showed synergistic effects on ethanol and anti-tubercular drugs induced 
hepatotoxicity models by significantly decreasing the liver damage. 
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INTRODUCTION 
Liver is one of the heaviest and largest organ which plays a vital role 
in metabolism of carbohydrate, fat and protein, involved in the 
secretion of bile and also detoxifies and excretes xenobiotics and 
drugs [1]. Since the liver is involved in biotransformation and 
excretion of the external chemicals, the exposure to these chemicals 
in significant concentrations may cause to improper functioning and 
injury to the cell may, which leads to organ failure. 
The usual causative agent which causes liver injuries is toxic 
chemicals, drugs, alcohol consumption and microbial agents [2]. 
Consumption of alcohol leads to various intra and extrahepatic 
diseases, metabolic disorders etc., as it gets oxidized to a toxic 
product called acetaldehyde, which causes alkylation of proteins and 
increases lipid peroxidation. Alcoholic liver disease is a major 
problem worldwide and has three main indications in the form of 
steatosis, hepatitis and cirrhosis [3]. Drug-induced liver injury is the 
major confront to the industries and RA, as it may be the main 
clinical problem which leads to liver failure and liver 
transplantation. An increasing number of acute liver failure cases 
have been reported every year and the drugs contribute the majority 
of them (eg: Anti-TB drugs, NSAID’s, Statins, etc) among which the 
anti-tubercular drugs-induced hepatotoxicity is the commonest, 
where the incidence of hepatotoxicity is higher (8-10%) in 
combination therapy of the first-line anti-TB drugs (isoniazid, 
rifampin) when compared to monotherapy (1-2%) [4]. 
Even though various synthetic drugs are available in the market to treat 
hepatic disorders, still there is a need for the development of new drugs 
to compensate their lack of efficacy and undesirable adverse effects. 
Hence, phytomedicines has a very crucial role in the treatment of hepatic 
disorders because of their fewer side effects and synergistic action when 
given in the form of combination [5]. In this regard, the current 
investigation involves the use of the combined extract of Momordica 
charantia [6] (Cucurbitaceeae) and Phyllanthus amarus [7] 
(Euphorbiaceae). Both the plants contain important phytoconstituents 
such as alkaloids, flavonoids, polyphenols, etc., and are reported to have 
anti-oxidant [8], anti-inflammatory [7], hepatoprotective [9] activities 
etc., Since this particular combination was not tested previously, an 
effort was made for evaluating the synergistic effect of the combination 
of plants Momordica charantia and Phyllanthus amarus for 
hepatoprotective activity on experimentally-induced various models of 
hepatotoxicity. 
MATERIALS AND METHODS 
Drugs and chemicals 
All the chemicals are of AR grade and were procured from SD Fine Chem 
Ltd., Mumbai. Drugs like isoniazid (Solonex DT), rifampicin (R-Cin 150 
mg capsule) and silymarin (Silybon 140 mg) were purchased from the 
commercial sources. All the drugs were freely soluble in distilled water 
and were administered orally for experimental purpose. 
Plant material 
Combination of the extract was obtained as gift sample from Green 
Chem Herbal Extracts and Formulations, Domlur, Bangalore. 
Experimental animals 
Healthy male wistar albino rats in the weight range of (150-200g) were 
procured from Commercial registered breeder for hepatoprotective 
activity. The experimental protocol was approved by IAEC, of KLE 
College of Pharmacy, Bengaluru (Ref. no. 02/PA/2018). 
Experimental design 
Acute oral toxicity study  
Acute oral toxicity study for the combined extract was conducted as 
per OECD TG 425. Healthy male wistar albino rats weighing 150-
180g were used. Weighed quantity of stock solution was prepared 
by dissolving the extract in distilled water. Aqueous combined 
extract at various doses up to 2000 mg/kg b. w by oral route were 
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administered. Following this, initially, the animals were observed 
carefully for the first 4 h, and daily thereafter up to 14days for any 
behavioral changes and mortality [10]. 
Hepatoprotective activity 
Ethanol-induced hepatotoxicity 
Healthy wistar albino male rats were chosen and randomly assigned 
into groups of five, where each group consists of 6 animals (n=6). 
Group I: Normal control. 
Group II: Positive control (50% ethanol 12 ml/kg b. w, p. o. for 8 d) 
Group III: Standard (Silymarin 100 mg/kg b. w, p. o)+Ethanol 
Group IV: MC+PA (Dose I 200 mg/kg b. w, p. o)+Ethanol 
Group V: MC+PA (Dose II 400 mg/kg b. w, p. o)+Ethanol 
Hepatotoxicity was induced by administering ethanol to all groups 
except group I for 8days. Group III, IV and V animals obtained treatment 
2hour prior to the ethanol administration. After the completion of the 
study on 8thday, 6hr after the last dose was given, blood samples were 
collected by retro-orbital sinus and then centrifuged for 10 min at 3000 
rpm for separating serum, which was used to carry out the biochemical 
estimations. Following this, the animals were sacrificed by an excess 
dose of anesthesia and the liver was isolated for histopathological study 
and to assess the antioxidant activity [11].  
Anti-tubercular drugs-induced hepatotoxicity  
Healthy wistar albino male rats were chosen and randomly assigned 
into groups of five, where each group consists of 6 animals (n=6). 
Group I: Normal control. 
Group II: Positive control (INH+RIF 50 mg/kg b. w each p. o)  
Group III: Standard (Silymarin 100 mg/kg b. w, p. o)+(INH+RIF) 
Group IV: MC+PA (Dose I 200 mg/kg b. w, p. o)+(INH+RIF) 
Group V: MC+PA (Dose II 400 mg/kg b. w, p. o)+(INH+RIF) 
Hepatotoxicity was induced by administering INH+RIF to all groups 
except Group I for 21days. Group III, IV and V animals obtained 
treatment 1hour prior to the ethanol administration. After the 
completion of the study on 21st day, 6hr after the last dose was given, 
samples of blood were collected by retro-orbital sinus and then 
centrifuged for 10 min at 3000rpm for separating serum which was used 
to carry out the biochemical estimations. Following this, the animals 
were sacrificed by an excess dose of anesthesia and liver was isolated for 
histopathological study and to assess the antioxidant activity [12].  
Evaluation of biochemical parameters 
The evaluation of biochemical parameters like AST, ALT, ALP, 
Bilirubin, Urea, Creatinine and Gamma GT in the serum were evaluated 
by Semi Auto Analyzer (RMS biochemical auto-analyzer Model: BCA 
201) using diagnostic kits (Agappe diagnostics, Kerala). Estimation of 
superoxide dismutase [13] levels and malondialdehyde [14] levels in 
liver tissue were carried out. 
Statistical analysis 
Values are expressed as mean±SEM, n=6; Statistical analysis by 
ANOVA Followed by Dunnett’s posttest using Graph-pad prism. 
Symbols represent statistical significance: #p<0.05, ##p<0.01, 
###p<0.001 when compared to normal. *p<0.05, **p<0.01,***p<0.001 
when compared to positive. 
RESULTS 
Acute toxicity test 
Acute oral toxicity for the combined extract was conducted as per 
OECD TG 425. There was no sign of behavioral changes and mortality 
and the combination tested was safe up to 2000 mg/kg b.w. 
Hepatoprotective activity in ethanol and Anti-tubercular drugs 
induced hepatotoxicity models 
The results of the ethanol-induced hepatotoxicity model are shown in 
table 1 and 2. Whereas, the results of anti-tubercular drugs-induced 
(INH+RIF) hepatotoxicity model are represented in table 2 and fig. 1, 2 
and 3. Oral administration of hepatotoxic agents like ethanol and 
INH+RIF showed a remarkable rise in the serum levels of AST, ALT, 
ALP, GGT, Urea and creatinine (biochemical markers). Whereas 
pretreatment with Silymarin (100 mg/kg) and MC+PA at various 
doses of 200 and 400 mg/kg significantly decreased the elevated 
profile of the serum biochemical markers when compared to positive 
groups of two models. Anti-oxidant status was measured using liver 
homogenate in both the models, and there was a significant reduction 
in SOD activity caused by ethanol and INH+RIF administration when 
compared with normal, which was enhanced by treating with the 
combined extract (MC+PA) at both doses and also by silymarin. 
Further, the hepatic MDA was also elevated significantly in the positive 
groups of two models. Pre-treatment with MC+PA (200 and 400 
mg/kg) and silymarin reduced the elevated concentrations of MDA in 
comparison with positive groups of two models (table 2). The 
histopathological results of positive groups of two models revealed 
mild degenerative changes of perivenular hepatocytes, distorted 
architecture, centrilobular necrosis and mild inflammatory cell 
infiltration. Pre-treatment with silymarin and MC+PA of various doses 
improved the damaged conditions caused due to ethanol and INH+RIF 
administration (fig. 4 and 5). 
 






Normal Positive (12 ml/kg) Standard (100 mg/kg) Dose I (200 mg/kg) Dose II (400 mg/kg) 
1 AST (U/l) 38.38±2.29 87.24±2.54### 45.65±2.03*** 54.09±2.34*** 49.14±3.53*** 
2 ALT (U/l) 29.08±1.40 70.42±5.88### 44.49±0.74*** 50.60±1.85** 47.11±2.06*** 
3 ALP (U/l) 61.41±3.93 115.96±3.97### 76.24±1.65*** 86.16±3.99*** 81.12±5.88*** 
4 GGT (U/l) 9.64±0.97 15.63±1.65## 11.00±0.49* 11.58±0.73* 11.19±0.92* 
5 Bilirubin (mg/dl) 0.29±0.04 2.07±0.38### 0.51±0.03*** 1.18±0.17* 0.81±0.17** 
6 Urea (mg/dl) 40.41±5.89 68.33±4.06### 50.83±2.10* 53.33±1.78* 51.66±6.11* 
7 Creatinine (mg/dl) 0.79±0.21 3.66±0.25### 1.22±0.35*** 1.45±0.30*** 1.36±0.28*** 
Values are expressed as mean±SEM, n=6. #p<0.05, ##p<0.01, ###p<0.001 when compared to normal.*p<0.05, **p<0.01, ***p<0.001 when compared to 
positive control.  
 
Table 2: Effect of MC+PA on Anti-oxidant status in Ethanol and Anti-tubercular drugs induced hepatotoxicity models 
  Normal Positive Standard Dose I Dose II 
1. Ethanol-induced hepatotoxicity a. SOD (U/mg prot) 17.41±1.17 6.39±0.95### 13.95±1.49*** 12.54±0.76** 13.24±1.08*** 
b. MDA (nmol/mg prot) 3.74±0.47 7.38±1.08## 3.88±0.42** 4.91±0.46* 4.22±0.28** 
2. Anti-tubercular drugs-induced 
hepatotoxicity 
a. SOD (U/mg prot) 17.41±1.17 5.43±0.92### 13.24±1.61*** 11.33±0.74** 11.90±0.89** 
b. MDA (nmol/mg prot) 3.74±0.47 9.44±1.35### 4.09±0.33*** 5.19±0.67** 4.56±0.55** 
Values are expressed as mean±SEM, n=6. #p<0.05, ##p<0.01, ###p<0.001 when compared to normal.*p<0.05, **p<0.01, ***p<0.001 when compared to 
positive control.  
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Fig. 1: Effect of MC+PA on serum AST, ALT, ALP and GGT levels in Anti-tubercular drugs-induced hepatotoxicity model, values are 














































Fig. 2: Effect of MC+PA on serum bilirubin and creatinine levels in Anti-tubercular drugs-induced hepatotoxicity model, values are 

















































Fig. 3: Effect of MC+PA on serum Urea levels in Anti-tubercular drugs-induced hepatotoxicity model, values are expressed as mean±SEM, 
n=6. #p<0.05, ##p<0.01, ###p<0.001 when compared to normal.*p<0.05, **p<0.01, ***p<0.001 when compared to positive control 
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Fig. 4: Effect of MC+PA on histopathological changes in Ethanol-induced hepatotoxicity model 
Surana et al. 













Fig. 5: Effect of MC+PA on histopathological changes in Anti-tubercular drugs-induced hepatotoxicity model 
Surana et al. 




The present study investigates the use of the combined extract of 
Momordica charantia and Phyllanthus amarus at different doses to 
evaluate the synergistic hepatoprotective activity in ethanol and 
anti-tubercular drugs-induced hepatotoxicity model in rats.  
Alcohol was identified as a direct hepatotoxin and metabolism of 
ethanol in the liver generates a reactive product called acetaldehyde, 
which is highly toxic even at its low concentrations in the blood 
which leads to oxidative stress, hypoxia, immunological mechanisms 
and carcinogenesis. The drug isoniazid reacts with macromolecules 
to form toxic acetyl-hydrazine and hydrazine. Rifampicin 
synergistically acts with isoniazid and increases the rate of 
formation of toxic metabolites leading to liver necrosis. Under liver 
injury conditions, there is a loss of structural integrity of the 
hepatocytes where the liver functional markers get released into 
circulation, which results in an elevation in their levels.  
AST and ALT are primarily present in the liver, whereas ALP may be 
produced from heart, kidney, bone, placenta, liver and intestine. 
When there is no evidence of bone disease and pregnancyit can be 
confirmed that the elevation of ALP is due to hepatobiliary disease. 
Bilirubin is an important indicator of liver function and it can only be 
confirmed in in vivo models. Elevated profile is seen in the 
conditions of icterus, hepato-biliary disease, Drug-induced liver 
injury etc. GGT is an enzyme mainly present in the liver, renal 
tubules, intestinal cells, etc. and is found to be elevated in individuals 
with alcohol abuse and hepatobiliary disease. 
Elevated concentrations of ALP, GGT and Bilirubin cause hepatobiliary 
obstruction and leads to alcoholic liver disease. Impairment of liver 
function lead to an increase in urea and creatinine levels in positive 
group of both models compared to normal control which is because of 
the circulatory changes, changes in blood flow and blood vessel tone of 
the kidney, which demonstrates nephrotoxicity along with 
hepatotoxicity. This is due to the condition called as Hepato-renal 
syndrome, which usually develops due to liver cirrhosis, alcoholic 
hepatitis and fulminant liver failure [15, 16]. 
This work clearly demonstrates that the MC+PA and the standard 
Silymarin significantly decreased the elevated profiles of the serum 
enzymes, bilirubin, thereby improving the hepatobiliary function. 
And also the levels of urea and creatinine were decreased in 
comparison with the hepatotoxic group of ethanol and anti-TB 
drugs-induced hepatotoxicity models by exhibiting the 
nephroprotective effect along with the hepatoprotective activity. 
The damage to the hepatic parenchymal cells due to toxins acting on 
the liver leads to the formation of reactive oxygen species (ROS) 
which further leads to oxidative stress. In oxidative stress condition, 
there is an imbalance between the levels of ROS and intrinsic anti-
oxidant enzyme system, which causes oxidation of lipids and 
proteins, DNA damage, etc. SOD is one of the important antioxidant 
enzymes which catalyze the dismutation of superoxide radicals to 
produce H2O2 and molecular oxygen, hence diminishing the toxic 
effects caused by the radical. Measurement of MDA is an index of 
lipid peroxidation. Standard and MC+PA (200 and 400 mg/kg) 
increased the SOD levels and decrease the MDA concentrations thus 
contributing to its potential antioxidant effect.  
The above results were supported by the histopathological changes 
in liver tissues. The combined extract exhibited a potent 
hepatoprotective role in a dose-dependent manner by improving the 
pathological changes caused by ethanol and anti-tubercular drugs. 
There is a need for further investigations to understand the 
mechanism of action of the plant extract through which it is 
exhibiting the hepatoprotective effect. From the above results, it can 
be concluded that the synergistic effect of the combined extract is 
may be due to the presence of phytoconstituents like flavonoids, 
alkaloids, and polyphenols which are highly responsible for 
exhibiting hepatoprotective and anti-oxidant activities. Hence, this 
study represents a novel and attractive ideas to prevent the hepatic 
injury caused due to the consumption of ethanol and the drugs used 
in anti-tuberculosis treatment. 
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